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Abstract
Background
The narrative surrounding the management of potentially resectable pancreatic cancer is
complex. Surgical resection is the only potentially curative treatment. However resection
rates are low, the risk of operative morbidity and mortality are high, and survival outcomes
remain poor. The aim of this study was to create a prognostic Bayesian network that pre-
operatively makes personalized predictions of post-resection survival time of 12months or
less and also performs post-operative prognostic updating.
Methods
A Bayesian network was created by synthesizing data from PubMed post-resection survival
analysis studies through a two-stage weighting process. Input variables included: inflamma-
tory markers, tumour factors, tumour markers, patient factors and, if applicable, response to
neoadjuvant treatment for pre-operative predictions. Prognostic updating was performed by
inclusion of post-operative input variables including: pathology results and adjuvant therapy.
Results
77 studies (n = 31,214) were used to create the Bayesian network, which was validated
against a prospectively maintained tertiary referral centre database (n = 387). For pre-oper-
ative predictions an Area Under the Curve (AUC) of 0.7 (P value: 0.001; 95% CI 0.589–
0.801) was achieved accepting up to 4 missing data-points in the dataset. For prognostic
updating an AUC 0.8 (P value: 0.000; 95% CI:0.710–0.870) was achieved when validated
against a dataset with up to 6 missing pre-operative, and 0 missing post-operative data-
points. This dropped to AUC: 0.7 (P value: 0.000; 95% CI:0.667–0.818) when the post-oper-
ative validation dataset had up to 2 missing data-points.
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Conclusion
This Bayesian network is currently unique in the way it utilizes PubMed and patient level
data to translate the existing empirical evidence surrounding potentially resectable pancre-
atic cancer to make personalized prognostic predictions. We believe such a tool is vital in
facilitating better shared decision-making in clinical practice and could be further developed
to offer a vehicle for delivering personalized precision medicine in the future.
Introduction
Pancreatic cancer is one of the most aggressive and challenging malignancies and is the fourth
and fifth most common cause of cancer deaths in the USA and Europe respectively [1,2]. Over-
all 10-year survival of all cases diagnosed has remained at less than 1% despite advances in the
fields of oncological therapies, surgical techniques and diagnostic technologies [3]. The
reported percentage of cases amenable to surgical resection has been reported to be as low as
9.8% [3] and it is the narrative surrounding the management of potentially resectable cases of
pancreatic cancer that is most complex, not least due to the ambiguities and controversies
within the existing body of evidence.
The only potential cure for pancreatic cancer is surgical resection [3,4]. Adjuvant therapy
has been proven to prolong survival with its role in the management of resected pancreatic
cancer established through successive randomize controlled trials [4]. Therefore, surgery fol-
lowed by adjuvant therapy has become the standard of care for resectable pancreatic cancer
[4]. However such a narrative does not convey the full message contained within the empirical
data.
Whilst it is true that surgical resection is the only potentially curative treatment, 5-year sur-
vival for resected cases of pancreatic cancer stands at between 7% and 25% [3]. Up to 50% of
patients fail to receive adjuvant therapy due to post-operative complications, early disease
reoccurrence and decline in function [5,6]. Consequently the potential benefits of such high-
risk surgery, with its impact on quality-of-life, are often nullified.
The narrative becomes even more complex when considering the emerging role of neoadju-
vant therapy as an alternative treatment pathway. Postulated benefits of this approach include:
avoidance of futile surgery by identifying more aggressive tumours, eliminating micrometa-
static disease to prevent early disease reoccurrence, increased R0 resection rates, and comple-
tion of multimodal treatment [7,8]. However, there is currently a lack of randomized
controlled trials offering direct comparison between neoadjuvant and surgery-first approaches
for resectable pancreatic cancer [9] and critics highlight the dangers of drawing optimistic con-
clusion regarding neoadjuvant therapy from a body of mainly small, underpowered studies
[7,8]. Whilst the role of neoadjuvant therapy in the management of borderline resectable and
locally advanced cases of pancreatic cancer has widely been accepted due to the potential bene-
fits of conversion to resectability and achieving R0 resection [7,8], studies synthesizing the
results of existing trials have reported only marginal benefits with neoadjuvant therapy [9–15].
Its role in the management of resectable pancreatic cancer remains controversial due to the
potential risk of losing the window of resectability.
The question therefore arises as to how we can better communicate and transmit complex
and data rich narratives to patients about their prognosis following a diagnosis of potentially
resectable pancreatic cancer to facilitate better shared decision-making. Personalized predic-
tive modeling, whereby patients are provided with forecasts of outcomes across competing
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treatment strategies, has gained precedence within contemporary medicine [16,17]. Its impact
on the management of pancreatic cancer, considering the low surgical volume, high operative
morbidity and mortality, and poor survival outcomes, could be significant through more effec-
tive patient counseling, risk-stratification and improved treatment selection [18]. However
existing prognostic models fall short of achieving this goal and are seldom applied in the clini-
cal settings [18]. The majority are based on single centre data which potentiates bias and limits
generalizability, and few have undergone external validation. This is partly due to the fact that
acquisition of large databases of potentially resectable cases is difficult as the majority of cases
present with advanced disease [3]. Furthermore existing models predominately rely on post-
operative data and are mainly based on traditional non-linear regression techniques which fail
to encompass the dynamic nature of the care process whereby predicted outcomes evolve as
events unfold, such as treatment complications, and time-dependent information emerges,
such as post-operative pathological assessment of the resected tumour [19].
The aim of this study was to combine PubMed and patient level data to create and validate
a prognostic Bayesian network that will make personalized predictions of poor prognostic out-
come (defined as 12months or less survival time) post resection of pancreatic ductal adenocar-
cinoma (PDAC).
Materials and methods
Bayesian network
Based on probability theory, Bayesian networks (BN) model relationships between variables
based on a graphical formalism of a joint or multivariate probability distribution over a set of
variables. This is formalized as: BN = (G,Pr). G is a graphical structure and Pr is the probability
distribution [16,19,20–22]. Within the graphical structure of a BN, G, variables are modeled as
nodes (V(G)) with causal relationships between parent and child nodes represented by
directed arcs (A(G)) therefore G = V(G), A(G). Within a BN any number of nodes can be
included therefore V(G) = {V1, V2. . ..Vn} where n>1. Directed arcs, A(G), represent the prob-
abilistic influence between parent (Vi)and child (Vj) nodes: Vi Vj [16,19,20–22].
The dependence and independence between nodes is defined by the joint probability distri-
bution (Pr):
Prðxi . . . :xnÞ ¼
Q
i Pr
xi
pai
� �
where xi represents the value of variable xi and pai represents a set of values for the parents of
xi which gives the conditional probability distribution[16,19,20–22]. Furthermore each vari-
able within the network is independent of non-descendent nodes:
Prðx4jx1; x2; x3Þ ¼ Prðx4jx2; x3Þ
whereby x2 and x3 are the parents of x4 which is independent of x1 therefore each node has a
conditional probability table representing the probability of each value contained within that
node given the condition of all its parent nodes [20–22]. Through Bayes theorem the prior dis-
tribution and observed data are combined to update knowledge in the form of the posterior
distribution [20]. Missing data is handled through probabilistic inference with predictions
made based on global averages of the patient population [19,22]. In this way BN allow the
modeling of the dynamic relationships between variables contained within the complex
healthcare process, with predictions evolving and accuracy improving as more information
becomes available [17,19].
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Evidence synthesis
PubMed database was searched following the PRISMA guidelines [23] (S1 Fig) with the entire
database included from 1st January 2000 up to and including 3rd December, 2018 using the full
list of search terms provided in supplementary material (S1 Table). The inclusion criteria were
full-text multivariable survival analysis studies of patients aged 18years or over that had under-
gone resection of PDAC whether treated in neoadjuvant or upfront surgery pathways.
Included studies had to report the results of survival analysis of patients who had undergone
resection of PDAC where the aim of the study was to identify variables associated with a post
resection survival time of 12months or less. Studies that included other subtypes of pancreatic
cancer and observational and cohort studies that reported only survival outcomes without
multivariate analysis of variables associated with the survival outcome in question were
excluded. Reference lists and citations of all included papers were also manually screened to
identify any additional articles. This was repeated until no new articles were identified. All
manuscripts were assessed using a combination GRADE guidelines [24], and Zhu et al. [25]
checklist of items for evaluating the quality of reporting of survival-analysis. Studies of poor
quality and with a high risk of bias were excluded.
The first author performed search design and data extraction. The second author per-
formed independent data extraction and quality assurance. Data was extracted manually from
studies and included: study year, number of included patients, risk-of-bias information, all
variables that were included in the multivariate analysis, and for each variable whether it was
found to have a statistically significant association with poor prognosis post resection of
PDAC as defined by a P value <0.005. Inter-reviewer discussion resolved any discrepancies.
This yielded 77 papers, giving a pool of n = 31,214 patients from which the model was built (S2
Table).
Adapting methods from Zhao and Weng [26], extracted data underwent a two stage weight-
ing process. The original weight for each variable (woi) represents a summary of existing evi-
dence, including conflicting findings [26], and was calculated as woi = Pi/Ni where Ni
represents the total number of times in the body of evidence that the variable was included in
multivariate analysis and Pi represents the number of times where the variable was found to be
statistically significant in its association with a poor post resection prognosis. A process of nor-
malization, adapted from Zhao and Weng [26], was then undertaken to place this ratio in the
context of the entire PubMed body of evidence related to each variable and poor post resection
prognostic outcome. Normalized weights, wi, were defined as:
wi ¼ w�ið
maxðpw�1; pw�2; . . . pw�nÞ
maxðps1; ps2; . . . psnÞ
Þ
The sum of the study populations reporting the variable, (pw0), is defined as max(pwo1,
pwo2, . . .. pwon). The sum of the study populations of all included studies is defined as max(ps1,
ps2,. . .psn). Both weights are therefore defined on a scale of 0 to 1, with the normalized weight-
ing used to rank each variable in order of significance (Table 1).
Bayesian network structure
The top 25 ranking variables (Table 1) were used to structure the BN created using AgenaRisk
version 7.0 software [27]. Variables known pre-operatively were used to construct the pre-
operative version of the model (Fig 1) with post-operative variables added to perform prognos-
tic updating (Fig 2). Each variable was treated as a ranked parent node and were linked to their
respective child nodes through causative arcs.
Changing the narrative of pancreatic cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0222270 September 9, 2019 4 / 14
Table 1. Weighted variables from synthesized PubMed studies (n = 31214).
Variable/ Node Node Status Definition Rank based on normalized
weighting
Lymph Node Positive Yes
No
1
Lymph node ratio <0.3
>0.3
Ratio of the number of positive lymph nodes to the total number of lymph
nodes removed
2
Tumour Grade G1/G2
G3/G4
As per American Joint Committee on Cancer definition [19]: Well/
moderate differentiation, low/intermediate grade
Poorly differentiated, high grade
3
Tumour Size < 2cm
>2cm
4
R0 Resection No
Yes
No microscopic evidence of any residual tumour 5
Adjuvant Therapy No
Yes
6
T stage T1
T2
T3
T4
7
Pre treatment Ca 19–9 <50
50–999
>1000
<50 U/mL
50–999 U/mL
>1000 U/ mL
8
AJCC (American Joint Committee
on Cancer) Stage
0
1
2
3
4
As per AJCC definition 9
Vascular Involvement Yes
No
10
Perineural Involvement (PNI) Yes
No
11
Age < 70
>70
Under 70 years
Equal to or over 70 years
12
mGPS (modified Glasgow
Prognostic Score)
0
1
2
0 = CRP</ = 10mg/L and albumin >/ = 35 g/L
1 = CRP > 10mg/L
2 = CRP> 10mg/L and albumin <35 g/L
13
CEA>5 <5
>5
<5 ng/mL
>5 ng/mL
14
Performance Status
Good
Moderate
Poor
As defined by American Society of Anaestheologits (ASA) classification
ASA 1–2
ASA 2–3
ASA >3
15
Tumour Location HOP
Body/Tail
Head of Pancreas (HOP)
Location other than HOP
16
Post treatment Ca19-9 <120
>120
<120 U/mL
>120 U/mL
17
Prei operative Blood Transfusion Yes
No
18
Albumin Normal
Low
= /> 35 g/l
< 35 g/l
19
Neutrophil Lymphocyte Ratio <5
>5
20
Jaundice No
Yes
Bilirubin < 40μmol/l
Bilirubin >40μmol/l
21
Diabetes No
Yes
22
(Continued)
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To calculate the node probability table for each child node, the normalized weighting of
each parent node was used as the weighted mean of the truncated Normal (TNormal) distribu-
tion. The final output node was a Boolean node whereby a 50% or greater probability of ‘yes’
for 1year survival or less was accepted as predicting poor prognosis post resection. It was calcu-
lated from the weighted mean of the corresponding parent nodes. The TNormal statistical dis-
tribution was used as it has been proven to generate accurate node probability tables for BN
involving ranked nodes with ranked parent nodes [20].
The definitions and categorization of input data for each node within the BN are detailed in
Table 1. These definitions and categorizations were determined by how this data was presented
Table 1. (Continued)
Variable/ Node Node Status Definition Rank based on normalized
weighting
Smoking Non-smoker
Smoker
23
Response to Neoadjuvant
Treatment
Stable
Progression/
Unresectable
Radiological response or stable disease that is still resectable
Radiological evidence of progression/ unresectable disease
24
BMI Normal
Low
Body Mass Index (BMI) above 18
BMI equal or under 18
25
https://doi.org/10.1371/journal.pone.0222270.t001
Fig 1. Bayesian network to predict poor post resection prognosis. Parent nodes in white, child nodes in green and output node in purple.
https://doi.org/10.1371/journal.pone.0222270.g001
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in the published studies and they, as well as the overall model structure, were approved by an
expert panel of pancreatic surgeons.
Model validation
The performance of the model was assessed using the area under the curve (AUC) of the
received operated curve (ROC) using SPSS Statistics version 24 software. It was validated
against a 20year, prospectively maintained patient database from a tertiary referral centre.
Individual patient data was entered into the BN and the personalized pre and post-operative
predictions of poor prognosis were recorded and assessed against that individual’s actual sur-
vival time therefore deeming predictions to be true or false. All patients who had survival data
recorded, had died, or if still alive had a survival time beyond 12 months, and who, for the
post-operative BN had post-operative data available, were included. Patients who were found
to have non-resectable disease at operation, or who were treated in a neoadjuvant pathway and
were found to have non-resectable disease at re-staging, were included to reduce the risk of
bias when validating the pre-operative BN as in the clinical setting the intention would have
been to perform resection. This gave a pool of 387 and 251 patients against which the predic-
tive performance of the pre and post-operative models were validated respectively.
Fig 2. BBN to predict poor prognosis post resection. Pre-operative and post-operative parent nodes in white, pre-operative child nodes in
green, post-operative child nodes in blue and output node in purple.
https://doi.org/10.1371/journal.pone.0222270.g002
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Results
Pre-operative predictions
The database against which the BN was validated did not contain data on tumour markers
Ca19-9 and CEA, which were the third and seventh ranked pre-operative nodes respectively
(Table 1). Despite this missing data the model achieved an AUC of 0.7 (P value 0.001; 95% CI
0.589–0.801) where data on all other nodes were available (Fig 3). A statistically significant
AUC of 0.7 was maintained when an additional one and two data points were missing
(Table 2). At the point where an additional three data points were missing the AUC remained
above 0.6 but lost statistical significance (Table 2).
Prognostic updating
In addition to the absence of data on Ca19-9 and CEA in the pre-operative validation dataset,
data on post-treatment Ca19-9 levels, the 17th highest ranked variable (Table 1) was also miss-
ing from the validation dataset. Despite this the post-operative model maintained an AUC of
0.8 (P value: 0.000; 95% CI: 0.678–0.862) when all other data was available (Fig 4). An AUC of
Fig 3. Receiver operated curve (ROC) for pre-operative predictions where all data was available apart from
tumour markers.
https://doi.org/10.1371/journal.pone.0222270.g003
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0.8 was maintained until greater than 6 pre-operative data points, and up to and including 2
post-operative data points, were missing which resulted in an AUC of 0.7 (P value: 0.000; 95%
CI:0.667–0.818) (Table 3). An AUC of 0.7 was then maintained even when the validation data
set could contain over 6 missing pre-operative data points and up to and including 4 missing
post-operative data points (P value: 0.000; 95% CI: 0.660–0.788).
Table 2. Results of model performance in handling missing data.
Validation Dataset AUC
2 data points missing (n = 123) 0. 7 (P value 0.001; 95% CI 0.589–0.801)
Std. Error: 0.54
3 data point missing (n = 139) 0. 7 (P value 0.001; 95% CI 0.578–0.786) Std. Error: 0.53
4 data points missing (n = 144) 0.7 (P value 0.001; 95% CI 0.591–0.791) Std. Error: 0.51
5 data points missing (n = 176) 0. 6 (P value 0.009; 95% CI 0.537–0.711) Std. Error: 0.44
6 data points missing (n = 189) 0.6 (P value 0.024; 95% CI 0.518–0.690) Std. Error: 0.44
6+ data points missing (n = 387) 0.6 (P value 0.559; 95% CI 0.502–0.617) Std. Error: 0.29
https://doi.org/10.1371/journal.pone.0222270.t002
Fig 4. Receiver operated curve (ROC) for post-operative predictions where all data was available apart from
tumour markers.
https://doi.org/10.1371/journal.pone.0222270.g004
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Discussion
By utilizing existing PubMed data in a unique way within a BN, prognostic predictions of
12months or less survival time post resection of PDAC were made at the pre-operative stage of
the patient journey with an AUC of 0.7 even when up to 4 data points were missing. The BN
also demonstrated its ability to perform prognostic updating at the post-operative stage of the
patient journey with an AUC of 0.8, which was maintained even when greater than 6 pre-oper-
ative, and 1 post-operative, data points were missing. Above this threshold for missing data an
AUC of 0.7 was achieved.
The performance of the BN compares favorably to existing predictive model development
studies aiming to predict poor post pancreatic cancer resection prognosis. Existing models
based on multivariate cox proportional hazard regression techniques report an AUC of
between 0.7 and 0.887 [28–31]. However many are based on single institution databases
[28,29,31] and failed to undergo external validation [28,29] One study, based on single institu-
tion data, used artificial neural network technique to predict 7month mortality post-resection
Table 3. Summary of performance for prognostic updating.
1 Missing Post-operative
Data points
1–2 Missing Post-operative
Data Point
1–3 Missing Post-operative
Data Points
1–4 Missing Post-operative
Data Points
2 Missing Pre-operative Data
Points
AUC 0.8;
Standard Error:0.47;
P value: 0.000;
95% CI: 0.678–0.862
(n = 117)
AUC: 0.8;
Standard Error:0.51;
P value:
0.000;
95% CI:
0.651–0.850
(n = 120)
2–3 Missing Pre-operative
Data Point
AUC: 0.8;
Standard Error:0.045;
P value: 0.000;
95% CI: 0.685–0.862
(n = 138)
AUC: 0.8;
Standard Error:0.045; P value:
0.000;
95% CI: 0.685–0.862
(n = 139)
2–4 Missing Pre-operative
Data Points
AUC: 0.8;
Standard Error: 0.042;
P value:
0.000;
95% CI: 0.708–0.872
(n = 135)
AUC: 0.8;
Standard Error: 0.045;
P value: 0.000;
95% CI: 0.681–0.858
(n = 140)
2–5
Missing Pre-operative Data
Points
AUC: 0.8;
Standard Error: 0.041;
P value:
0.000;
95% CI: 0.708–0.869
(n = 137)
AUC: 0.8;
Standard Error: 0.043;
P value:
0.000;
95% CI: 0.681–0.849
(n = 146)
2-6 Missing Pre-operative
Data Points
AUC: 0.8;
Standard Error:0.041;
P value:
0.000;
95% CI: 0.707–0.869
(n = 138)
AUC: 0.8;
Standard Error:0.043;
P value: 0.000;
95% CI: 0.665–0.832
(n = 155)
AUC: 0.8;
Standard Error:0.042;
P value:
0.000;
95% CI:
0.672–0.835
(n = 157)
>6 Missing Pre-operative
Data Points
AUC: 0.8;
Standard Error:0.041;
P value:
0.000;
95% CI: 0.710–0.870
(n = 139)
AUC: 0.7;
Standard Error:0.039;
P value:
0.000;
95% CI:
0.667–0.818
(n = 195)
AUC: 0.7;
Standard Error: 0.037;
P value: 0.000;
95% CI:
0.667–0.814
(n = 205)
AUC: 0.7;
Standard Error:0.033;
P value:
0.000;
95% CI: 0.660–0.788
(n = 251)
https://doi.org/10.1371/journal.pone.0222270.t003
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and reported an AUC of 0.6576 but did not perform external validation [32]. One study used
Bayesian modeling techniques and National Registry data to predict 6month, 1,3 and 5year
survival and achieved a c-statistic of 0.65 [33].
Strengths and limitations
This model is unique on several levels. Firstly the creation of a BN allowed the novel utilization
of knowledge from existing PubMed studies in a clinically more meaningful way for individual
patients and their clinicians. This also means that the model, based on the wider collective
body of existing evidence, overcomes the limitations of many existing models that lack gener-
alizability as they are largely based on single institutional database analysis with the potential
for inherent bias that this creates. This also allows the BN to make predictions even when data
is missing through probabilistic inference with predictions made based on global averages of
the patient population [19,22]. Secondly this model goes beyond the few existing nomograms
and prognostic models by providing personalized predictions based on pre-operative informa-
tion therefore being of more value in patient counseling and decision-making throughout the
patient journey. Thirdly this model is unique in its ability to make personalized predictions of
outcome across the competing treatment strategies of upfront surgery and neoadjuvant
approach.
One limitation of this model is that it is based on published survival analysis studies, which
are predominately single centre studies that also carry a risk of bias. Whilst the two-stage pro-
cess of weighting variables was designed to minimize the potential impact of such bias on the
BN, there is also the potential that new and emerging studies will alter the weightings of nodes
within the BN, particularly as the role of neoadjuvant therapy becomes more established with
its impact on survival time consequently becoming more widely analysed. The model would
also benefit from being validated against another institution’s database, particularly consider-
ing that data on tumour markers was absent from the validation dataset used in this study.
These nodes therefore relied on probabilistic inference to make predictions. It is a strength of
the model that an AUC of 0.8 was achieved under these circumstances. Considering that
tumour markers were the 8th, 14th and 17th ranked variables, it is possible that the performance
of the BN could be even stronger had data on tumour markers been available. To address this
and further refine the BN, the next phase will be to incorporate patient level data from large
international patient databases into the existing model so that the accuracy of predictions can
be further improved by combining the prior distribution and observed data to update the pos-
terior distribution through Bayes theorem [20].
Study impact
This study marks a potentially significant step towards to achieving the delivery of personal-
ized cancer care. In the clinical setting the BN presented here has the potential to have an
immediate impact on improving patient counseling and facilitating better shared decision-
making by providing a mechanism to communicate and transmit the complex and data rich
empirical narrative surrounding a diagnosis of potentially resectable pancreatic cancer to
patients on a personalized level. This includes being better able to explain the impact of “what
if” scenarios on anticipated prognosis such as not achieving R0 resection, or not receiving
adjuvant therapy even if R0 resection is achieved.
The second area of impact of this study is in directing future research. As patient databases
globally develop in complexity and mature, so too should predictive modeling become more
sophisticated at integrating multiple complex databases to make individualized patient predic-
tions and support clinical decision-making [34–37]. This coincides with the growing interest
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in precision medicine where it is anticipated that our understanding of disease at genomic
level will lead to gene-targeted therapies [35,36]. However, patients are more than their
genomes. By developing a predictive model that can integrate clinical, pathological, and bio-
chemical data to make meaningful personalized predictions of outcomes, this BN paves the
way for future versions of this BN to incorporate emerging genomic data hence creating a
vehicle for delivering truly personalized precision medicine and accelerating the clinical appli-
cation of our ever expanding knowledge-base [37].
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